

Journal Pre-proof

Neuroprotective effects of mitochondrial-targeted hydrogen sulphide donor, AP39 on H₂O₂-induced oxidative stress in human neuroblastoma SHSY5Y cell line

Lisette Sanchez-Aranguren , Mandeep Kaur Marwah ,
Sarah Nadeem

PII: S2667-1379(21)00024-2
DOI: <https://doi.org/10.1016/j.arres.2021.100024>
Reference: ARRES 100024



To appear in: *Advances in Redox Research*

Received date: 15 September 2021
Revised date: 10 November 2021
Accepted date: 10 November 2021

Please cite this article as: Lisette Sanchez-Aranguren , Mandeep Kaur Marwah , Sarah Nadeem , Neuroprotective effects of mitochondrial-targeted hydrogen sulphide donor, AP39 on H₂O₂-induced oxidative stress in human neuroblastoma SHSY5Y cell line, *Advances in Redox Research* (2021), doi: <https://doi.org/10.1016/j.arres.2021.100024>

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

© 2021 Published by Elsevier B.V.
This is an open access article under the CC BY-NC-ND license
(<http://creativecommons.org/licenses/by-nc-nd/4.0/>)

Highlights

- The mitochondrial-targeted hydrogen sulphide donor, AP39 did not exhibit cytotoxic effects in SHSY5Y cells.
- AP39 generates H₂S intracellularly and in co-localisation with the mitochondria.
- AP39 promotes the cellular bioenergetics in SHSY5Y.
- AP39 reduces mitochondrial reactive oxygen species.

Journal Pre-proof

Neuroprotective effects of mitochondrial-targeted hydrogen sulphide donor, AP39 on H₂O₂-induced oxidative stress in human neuroblastoma SHSY5Y cell line

Lisette Sanchez-Aranguren^{1,2*}, Mandeep Kaur Marwah^{1,2}, Sarah Nadeem¹

¹College of Health and Life Sciences, Aston Medical School, Aston University, Birmingham, United Kingdom.

²Translational Medicine Research Group, Aston Medical School, Birmingham, United Kingdom.

*Correspondence:

Dr. Lisette Sanchez-Aranguren. Email: l.sanchez-aranguren2@aston.ac.uk

ORCID ID: <https://orcid.org/0000-0002-4663-5752>

Journal Pre-proof

Abstract:

Oxidative stress (OS) resulting from imbalance in the generation of reactive oxygen species (ROS) and/or the dysfunction of the antioxidant machinery, is a key mechanism associated with the onset of neurodegenerative disorders. Although the molecular mechanisms are still elusive, the onset of disorders such as Alzheimer's and Parkinson's disease have been associated with mitochondrial dysfunction. Recently, a mitochondrial-targeted hydrogen sulphide (H₂S) donor, AP39, has shown to promote cellular bioenergetics in OS related scenarios. The aim of this study was to explore the potential of AP39 to protect the mitochondrial function in an OS environment induced by hydrogen peroxide (H₂O₂). We assessed the potential effects of increasing concentrations of AP39 on cell viability, H₂S availability and the mitochondrial bioenergetic response in resting (non-differentiated and differentiated) neuroblastoma SHSY5Y cell line. Further, we explored the role of AP39 in attenuating H₂O₂-induced mitochondrial dysfunction. Our results showed that nanomolar to micromolar concentrations of AP39 (0.1 μM – 3 μM) are not toxic to SHSY5Y cells, regardless of their differentiation status. Fluorescence detection of H₂S observed AP39 co-localises within the mitochondria in a concentration dependent manner. Whilst a lower concentration of AP39 (0.3 μM) was required to improve the mitochondrial bioenergetics in resting non-differentiated cells, 1 μM produced this effect in their differentiated counterparts. In both, non-differentiated and differentiated cells, AP39 reduced H₂O₂-induced mitochondrial impairments by improving the parameters of the mitochondrial function and abrogating the generation of mitochondrial ROS. These suggest that mitochondrial targeted delivery of H₂S may attenuate neuronal toxicity in neuronal disorders associated with OS-induced mitochondrial dysfunction.

Keywords: Oxidative stress, neurodegenerative disorders, mitochondrial dysfunction, hydrogen sulphide donors.

Abbreviations:

ADTOH: 5-(4-hydroxyphenyl)-3H-1,2-dithiole-3-thione.

6-OHDA: 6-hydroxydopamine.

ATP: Adenosine triphosphate.

AD: Alzheimer's disease.

AA: Antimycin.

FCCP: Carbonyl cyanide 4-(trifluoromethoxy) phenylhydrazone.

H₂O₂: Hydrogen Peroxide.

H₂S: Hydrogen sulphide.

MAP-2: Microtubule-associated protein 2.

mt-ROS: Mitochondrial reactive oxygen species.

OXPPOS: Oxidative phosphorylation.

OS: Oxidative stress.

OCR: Oxygen consumption rates.

PD: Parkinson's disease.

ROS: Reactive oxygen species.

RA: Retinoic acid.

Rot: Rotenone.

SEM: Standard error of mean.

SF7-AM: Sulphideflour-7 acetoxymethyl ester.

TPP⁺: Triphenylphosphonium.

Introduction:

Neurodegenerative disorders occur due to the progressive and irreversible degeneration of nerve cells [1]. These conditions are characterised by the loss of vulnerable neuron populations, leading to impaired movement (ataxias) and changes in cognitive functions. Some commonly known neurodegenerative disorders include Alzheimer's disease (AD) and Parkinson's disease (PD) [1]. AD is the most common cause of dementia, mainly affecting people over the age of 65 [2] while PD is a neurodegenerative movement disorder associated with selective loss of dopaminergic neurons in the substantia nigra of the brain [3]. The pathophysiology of both conditions has been linked to enhanced production of reactive oxygen species (ROS) [4,3] and impaired mitochondrial bioenergetics [5,6]. Mitochondria are the primary site of energy production within cells [7]. Mitochondrial oxidative phosphorylation (OXPHOS) provides energy for neural activity by way of adenosine triphosphate (ATP) production [8]. This process continuously produces ROS as a physiological by-product. However, dysregulation of cellular antioxidant activity and/or imbalance in ROS production may cause oxidative stress (OS) [9].

Hydrogen sulphide (H_2S) is a gaseous signalling molecule that can stimulate physiological responses in various tissues, including the central nervous system [10]. Within optimal concentrations, H_2S promotes mitochondrial biogenesis and bioenergetics, thereby conferring protection against cellular stress [11]. H_2S donors show potential therapeutic value against neurodegenerative disorders due to their ability to produce anti-oxidant, -inflammatory, and -apoptotic effects in pathological situations. In this regard, H_2S donors have been shown to reduce cytotoxicity, intracellular protein oxidation, and lipid peroxidation in human neuroblastoma cell line SHSY5Y exposed to hypochlorous acid and 4-hydroxynonenal, which are increased in the temporal and frontal cortex of patients with AD [12,13]. Moreover, a rat model of PD, have shown a significant reduction of the endogenous H_2S production in the substantia nigra of 6-hydroxydopamine (6-OHDA) exposed rats [14] whilst the administration of H_2S donors have shown to protect against rotenone-induced apoptosis [15] and 6-OHDA-induced cytotoxicity [16] by preserving mitochondrial function [10].

Recently, a mitochondrial-targeted H_2S donor, named AP39 was synthesised [17,18]. AP39 has shown potential for attenuating mitochondrial-associated OS by exerting cytoprotective effects and reducing mitochondrial DNA oxidative damage [17]. Administration of AP39 after cardiopulmonary resuscitation showed an improvement in neurological function and survival rate in mice by maintaining mitochondrial integrity and reducing ROS [19]. AP39 has also potential for modulating neuroinflammation as demonstrated in reducing cytokine release in brains areas affected by ischaemia in rats [20].

The aim of this study was to explore the potential of AP39 to protect neuronal mitochondrial function in an OS environment induced by hydrogen peroxide (H_2O_2). We assessed the effects of increasing concentrations of AP39 on cell viability, H_2S availability and mitochondrial bioenergetics response in resting (non-differentiated and differentiated) neuroblastoma SHSY5Y cell line. Here, we report that AP39 targets delivery of H_2S to the mitochondria and attenuate H_2O_2 -induced mitochondrial dysfunction by improving the parameters of the mitochondrial function and abrogating the generation of mitochondrial ROS (mt-ROS).

Materials and methods:**Reagents:**

AP39 (Cambridge Biosciences, UK) is a H_2S donor consisting of the mitochondria targeting triphenylphosphonium (TPP^+) group ester-linked with the H_2S donor ADTOH (5-(4-hydroxyphenyl)-3H-1,2-dithiole-3-thione) by a ten-carbon alkyl chain (**Figure 1**). All-trans retinoic acid (RA) and H_2O_2 were obtained from Sigma Aldrich (Sigma Aldrich, USA).

Cell culture and differentiation

SHSY5Y neuroblastoma cells were maintained in RPMI 1640 (Gibco, UK) containing 5% FBS and 2 mM glutamine at 37°C in a humidified atmosphere of 5% CO₂. Cells were maintained up to passage 23. Differentiation to a more mature neuronal-like phenotype (d-SHSY5Y) was ascertained by culturing in low FBS (1%) RPMI 1640 supplemented with 10 µM of RA for 6 days. Briefly, cells were plated and left to attach overnight (day 0), at day 1, cell culture media was replaced to differentiation media (1% FBS and 10 µM RA). Medium was replaced with fresh differentiation media every 48h. Differentiation was measured by the extension of long neurites and detected by immunocytochemistry using antibodies against microtubule-associated protein 2 (MAP-2) (Sigma Aldrich, USA, catalogue # MA512826, 1:100). Cells were grown on glass coverslips (200K cells per coverslip). After differentiation, cells were washed in warm PBS and fixed in cooled ethanol for 5 minutes. Coverslips were permeabilised in 0.15% triton X-100, blocked in 10% goat serum blocking buffer for 1 h and incubated with first antibodies (overnight), followed by Alexa fluor (488) conjugated secondary antibodies (Abcam, UK, catalogue # ab175658, 1:500). Coverslips were mounted in glass slides using SlowFade™ Diamond Antifade Mountant (Thermo Fisher Scientific, UK). Staining was visualised using a Nikon Eclipse Ti-E inverted microscope using 60x objective lens. Images were recorded and quantification of immunofluorescence intensity performed in 50 cells at day 6, for each differentiation treatment.

Cell treatments with AP39 and H₂O₂

SHSY5Y and d-SHSY5Y were exposed to increasing concentrations of AP39 (0.1-10 µM) for 24 h in order to assess the effects of AP39 on cell viability. For other experimental protocols either resting cells or H₂O₂-stimulated neuroblastoma cells were exposed to (0.1-1 µM) AP39 for 1h as indicated in every figure legend. H₂O₂ (150-300 µM) was administered for 1 h alone or in combination with AP39 as indicated in the figure legends.

Cell viability

The cytotoxicity profile of AP39 towards SHSY5Y and d-SHSY5Y cells was determined with a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. The MTT is metabolised by viable cells to a purple coloured formazan. Briefly, SHSY5Y and d-SHSY5Y were plated at a cell density of 2.0 x 10⁴ cells/well in 96-well plates and left to attach overnight. After cell attachment, cells were exposed to AP39 (0.1-10 µM) for 24 h. Next, cell media was removed and MTT reagent (0.5mg/mL) dissolved in RPMI 1640 was added to each well and cells incubated at 37°C in a humidified atmosphere of 5% CO₂ for 1.5 h. MTT reagent was then aspirated and formazan solubilised in DMSO. Absorbance was recorded using a Tecan plate reader at 570nm.

Determination of intracellular H₂S by fluorescence

H₂S availability was evaluated in cells using the specific fluorescent probe Sulphidefluor-7 acetoxymethyl ester (SF7-AM) (Sigma Aldrich, USA) as previously described [21]. Briefly, cells (SHSY5Y and d-SHSY5Y) were plated in 24 well plates at a cell density of 8.0 x 10⁴ cells/well and left to attach overnight. Next, cells were exposed to AP39 (0.1-10 µM) for 1 h and then incubated with 2.5 µM SF7-AM in culture media for 30 min. Cells were washed twice with PBS and the fluorescence was measured at 495 nm/519 nm. Images were recorded at 20x using a Nikon Eclipse Ti-E inverted microscope. Analysis were performed using Image J.

Detection of mitochondrial reactive oxygen species (mt-ROS)

The generation of mt-ROS was ascertained using the fluorescent probe MitoSOX Red (Sigma Aldrich, USA) by fluorescent microscopy as previously reported [22]. Briefly, cells (SHSY5Y and d-SHSY5Y) were plated on coverslips (2.0 x 10⁵ cells/coverslip) and exposed to H₂O₂ and AP39 as described on the figure legends. Next, coverslips were washed in warm PBS and incubated with MitoSOX Red

(5 μ M) in PBS for 30 min, protected from light. Coverslips were carefully washed with PBS twice and fluorescence emitted at 580 nm was recorded and analysed using a Nikon Eclipse Ti-E inverted microscope using a 60 \times objective.

Cellular bioenergetics

Parameters of the mitochondrial function were assessed using an XF24 Extracellular Flux Analyser (Seahorse Biosciences/Agilent Technologies, UK) following protocols established in our lab [22,21,23]. Briefly, SHSY5Y and d-SHSY5Y were plated at 5.0×10^4 cells/well using V7 24 well plates (Agilent Technologies, UK) and cells left to attach overnight at 37°C in a humidified atmosphere of 5% CO₂. Following this, cells were washed and media replaced with non-buffered DMEM (10 mM glucose, 1 mM pyruvate and 2 mM L-glutamine) to allow temperature and pH equilibrium. The addition of AP39 and/or H₂O₂ was performed using the available ports of the XF24 Flux Analyser, prior to the injections of drugs/inhibitors used to calculate parameters mitochondrial function. Oxygen consumption rates (OCR) were measured before and after AP39/ H₂O₂ injection (first injection), followed by sequential injections of oligomycin (1 μ M) (Sigma Aldrich, USA), carbonyl cyanide 4-(trifluoromethoxy) phenylhydrazone (FCCP) (0.5 μ M) (Sigma Aldrich, USA) and a mixture of rotenone and antimycin A (Rot/AA) (1 μ M) (Sigma Aldrich, USA), to inhibit the ATP synthase, uncouple oxidative phosphorylation, and estimate non-mitochondrial respiration, respectively (75 μ L per injection). As previously described [24], injections of these reagents allow parameters of the mitochondrial function, including: basal, maximal respiration, spare respiratory capacity, ATP-linked OCR and proton leak to be determined. Data was expressed as the rate of oxygen consumption (pmolO₂/min/ μ g protein) by time. The concentration of proteins per well was assessed using BCA protein assay (Bio-Rad) after the completion of Seahorse assays.

ATP levels determination

The ATP Determination Kit (Invitrogen, USA) was used to measure levels of ATP in SHSY5Y and d-SHSY5Y exposed to AP39. Briefly, cells 5.0×10^4 cells/well were plated in 96-well plates, after overnight attachment, cells were exposed to AP39 for 1 h. After treatment, cells were processed as per manufacturer protocol and luminescence intensity was read using a Tecan microplate reader. Readings were expressed as percentage of control.

Mitochondrial isolation and detection of mitochondrial oxidated proteins

Isolation of mitochondria was performed using protocols available in our lab [23]. Briefly, SHSY5Y and d-SHSY5Y were grown in T125 flasks and exposure to H₂O₂ and AP39 was as described in the figure legend. Following this, mitochondria were isolated by cell disruption followed by differential centrifugation. Cells were scrapped in cold PBS and resuspended in mitochondrial isolation buffer (70 mM sucrose, 210 mM mannitol, 5 mM HEPES, 1 mM, EGTA, pH 7.4). Cells were disrupted and homogenised using needle syringe. Homogenates were then centrifuged for 10 min at 11,000 x g, 4°C. The resulting supernatant was centrifuged for 10 min at 11,000 x g, 4°C and the pellet (containing the mitochondria) resuspended in RIPA buffer containing protease inhibitors. Mitochondria was disrupted by needle syringe and centrifuged for 10 min at 10,000 x g, 4°C. Finally, the supernatant was collected, and protein concentration was measured by BCA protein assay (Bio-Rad). A concentration of 10 μ g of protein was used to evaluate the protein carbonyl formation, using the Protein Carbonyl Content Assay Kit (Abcam, catalogue # ab126287) as previously established in our lab and VDAC1 (porin), catalogue # ab34726 was used as the loading control.

Statistical analysis

Results are expressed as mean \pm standard error of mean (SEM). Statistical analysis was performed using GraphPad Prism software (version 8.1.0). A T-test was used to analyse the effects of differentiation conditions on MAP-2 expression between two groups (SHSY5Y and d-SHSY5Y) while

one-way analysis of variance (ANOVA) was employed to test the differences between more than two treatments. Post-hoc comparisons were made using the Tukey's multiple comparison's tests. All results are expressed as the mean of three independent experiments performed in triplicates. A $p < 0.05$ was considered statistically significant.

Results:

SHSY5Y differentiation

The differentiation of neuronal-like cells allows to obtain more mature neuron-like cell populations for *in vitro* testing [25]. To this end, using available protocols established in our lab, SHSY5Y were differentiated in low serum media containing RA (10 μM) for 6 days to obtain a more typical neuronal morphology [23]. As shown in **Figure 2A**, at days 0 cells display a characteristic undifferentiated phenotype with no particular neurite outgrow. At days 3-6, exposure to RA allowed the formation of dendrite-like projections. Successful differentiation was assessed by immunocytochemistry using antibodies against the neuronal marker, MAP-2 [26]. Differentiated SHSY5Y (d-SHSY5Y) showed an increased expression of MAP-2. By Day 6, the fluorescence intensity of MAP-2 increased approximately by 60% in comparison to SHSY5Y (**Figure 2B**). The differentiation was key for our next set of experiments in were we aimed to explore the effects of AP39 and to a non-toxic concentration of AP39 that would stimulate the mitochondrial bioenergetics while contrasting potential differences between non-differentiated and those displaying a more mature neuronal-like phenotype.

High concentrations of AP39 reduce SHSY5Y viability

The cytotoxicity profile of AP39 towards SHSY5Y and d-SHSY5Y cells was assessed with a MTT assay to establish suitable concentrations for following experiments. AP39 (0.1-3 μM) showed no statistical difference in the reduction of MTT reagent, representative of the viability of the cells. However, at 10 μM , AP39 demonstrated a reduction of both SHSY5Y and d-SHSY5Y cells' viability (**Figure 3A** and **3B**, respectively). Based on these observations and previous reports [21,19,27,28], we set the following experiments to a range of concentrations of AP39 between 0.1-1 μM .

AP39 accumulates within the mitochondria and releases H_2S

Once we established a range of AP39 concentrations not detrimental to cell viability, we aimed to explore whether these were sufficient to increase the intracellular availability of H_2S . Using the fluorescent probes; SF7-AM and Mitotracker Red, we observed that in both, SHSY5Y and d-SHSY5Y, non-treated cells (controls) displayed SF7-AM fluorescence with no mitochondrial preference. However, cells treated with AP39 (0.1-1 μM) induced a concentration-dependent increase in H_2S generation and these increased signals of SF7AM- H_2S detecting probe co-localised within the mitochondria (**Figure 4A** and **4B**, SHSY5Y and d-SHSY5Y, respectively). This suggests AP39 degrades within the mitochondrial compartment of cells to release H_2S .

Effects of AP39 on cellular bioenergetics in resting cells

The effects of AP39 on cellular bioenergetics was assessed in resting SHSY5Y and d-SHSY5Y (**Figure 5**) cells. We aimed to explore the effects of AP39 on human neuroblastoma cells' bioenergetics and to evidence whether the differentiation of SHSY5Y may have an impact on their response to AP39. In SHSY5Y we evidenced that AP39 (0.1-0.3 μM) induced a dose-dependent response in parameters of the mitochondrial function as evidenced by increased OCR, that resulted in increased basal respiration ($p < 0.05$) vs control (**Figure 5A** and **5B**). However, at 1 μM , a non-significant increase in OCR, similar to those induced by 0.1 μM was observed, suggesting that AP39 may have a biphasic effect on non-differentiated human neuroblastoma cells. The OCR-linked to ATP production, although not statistically different to control, suggested that AP39 may promote OXPHOS and therefore the mitochondrial generation of ATP (**Figure 5B**). Therefore, we assessed ATP levels and observed AP39 (0.3-1 μM) significantly increased ATP generation ($p < 0.05$ and $p < 0.01$ for 0.3 μM

and 1 μM AP39 exposed cells, respectively) (**Figure 5C**). Based on these observations, we recognised 0.3 μM as the optimal concentration of AP39 for SHSY5Y that would generate mitochondrial- H_2S while improving parameters of the mitochondrial function and selected this as the concentration to explore in further experiments.

The differentiation of SHSY5Y cells is accompanied by changes in mitochondrial metabolism and antioxidant defences in response to oxidative stress [26]. We aimed to explore whether these would impact the response to AP39 in resting conditions. Our experiments using the Seahorse-Agilent XF24 showed that AP39 (1 μM) significantly improved the basal and maximal respiration in comparison to non-treated cells (**Figure 5D** and **5E**). AP39 0.1-0.3 μM showed a dose-dependent response and a tendency to improve other parameters of the mitochondrial function such as the maximal respiration and ATP-linked OCR. Similar to our observations in SHSY5Y, we evidenced that AP39 improves the generation of ATP (**Figure 5F**). In contrast to our observations in SHSY5Y, we evidenced that for d-SHSY5Y, the optimum concentration of AP39 to stimulate the cellular bioenergetics was 1 μM . Therefore, further experiments using d-SHSY5Y were performed using an AP39 concentration of 1 μM .

AP39 improves cellular bioenergetics in cells challenged with H_2O_2

Next, we aimed to explore whether AP39 would protect against H_2O_2 -induced mitochondrial impairments and to contrast these effects between SHSY5Y and d-SHSY5Y. To verify our OS model, we exposed SHSY5Y to H_2O_2 for 1h (150-300 μM) and observed H_2O_2 (300 μM) led to a reduction in OCR levels, with significantly reduced basal and maximal respiration linked to a reduced generation of ATP (**Supplementary figure 1**). Then we exposed SHSY5Y and d-SHSY5Y to H_2O_2 and AP39 and evaluated the effects on the mitochondrial bioenergetics. To this end, we injected H_2O_2 , AP39 or H_2O_2 /AP39 directly to the wells using the first injection port available in the XF24 instrument. This approach allowed to evidence in real-time, the effects on OCR. H_2O_2 significantly reduced baseline OCR levels ($p < 0.001$ vs control and AP39) resulting in reduced basal respiration ($p < 0.05$ vs AP39 only) (**Figure 6A** and **6B**) and reduced maximal respiration ($p < 0.05$ vs control and AP39 only) (**Figure 6B**). However, whilst co-exposure of H_2O_2 and AP39 resulted in reduced basal respiration, it was enough to improve the maximal respiration (**Figure 6B**).

Figure 6C and **6D** shows the effects of co-exposure of H_2O_2 and AP39 to d-SHSY5Y. In contrast to our observations in SHSY5Y, we evidenced that H_2O_2 does not significantly reduce the baseline OCR and basal respiration in d-SHSY5Y. We only observed a significant impairment of the maximal respiration in H_2O_2 -exposed d-SHSY5Y ($p < 0.05$ vs control). The co-administration of H_2O_2 and AP39 showed a tendency to improve the basal respiration and maximal respiration to levels similar to non-treated cells (**Figure 6C** and **6D**).

AP39 reduces mitochondrial oxidative stress in cells exposed to H_2O_2

In order to study the overall mitochondrial oxidative status, we investigated the effects of AP39 in the generation of mitochondrial specific reactive oxygen species (mt-ROS) using the fluorescent probe MitoSOX Red and analysed mitochondrial protein carbonyls in isolated mitochondria by western blot. We analysed the effects of H_2O_2 on mt-ROS generation in both SHSY5Y and d-SHSY5Y. As shown in **Figure 7A** and **7B**, H_2O_2 (300 μM) increased the MitoSOX Red fluorescence signal. Interestingly, H_2O_2 -challenged SHSY5Y showed increased intensity of the signal when contrasted to d-SHSY5Y cells also exposed to H_2O_2 . These observations correspond to our observation in **Figure 6** where we found d-SHSY5Y are less affected by H_2O_2 exposure. In both, SHSY5Y and d-SHSY5Y, co-administration of H_2O_2 with AP39 (0.3 μM for SHSY5Y and 1 μM for d-SHSY5Y, respectively) showed a reduction in the MitoSOX fluorescence intensity, suggesting that under OS, AP39 is able to reduce the generation of mt-ROS. In line with these findings, SHSY5Y showed higher mitochondrial protein carbonyl content when compared to d-SHSY5Y (**Figures 7A** and **7B**, respectively). In SHSY5Y, AP39 was observed to reduce the mitochondrial protein carbonyl content in comparison to H_2O_2 -treated

SHSY5Y (**Figure 7A**). However, in d-SHSY5Y we evidenced that carbonyl content in AP39 co-treated with H_2O_2 was more evident in some molecular weight bands.

Discussion:

OS is a key component in the pathophysiology of several neurological conditions [29,30], including neurodegenerative disorders such as Parkinson's disease [3], and Alzheimer's disease [31,4]. In this study, we explored the potential of AP39, a novel mitochondrial-targeted H_2S donor, to protect against OS *in vitro*, contrasting the effects on non-differentiated and differentiated human neuroblastoma cell line SHSY5Y exposed to H_2O_2 . Our results suggest a broad range of AP39 concentrations are not cytotoxic to SHSY5Y while nanomolar concentrations of AP39 are sufficient to release therapeutic levels of H_2S in an OS cellular environment, favouring accumulation within the mitochondria. In addition, our results demonstrated AP39 was able to promote mitochondrial bioenergetics in both SHSY5Y and d-SHSY5Y, however, higher concentrations of AP39 are necessary to promote the mitochondrial bioenergetics in d-SHSY5Y in comparison to their non-differentiated counterparts. Linked to these observations, we observed AP39 stimulated the generation of ATP in resting cells. Finally, AP39 exerted protective effects in both SHSY5Y and d-SHSY5Y cells exposed to H_2O_2 by supporting the mitochondrial bioenergetics and reducing mitochondrial oxidative status.

There is an increased interest in the biology of H_2S as a large number of scientific reports have unravelled many of its downstream physiological effects [30]. H_2S not only supports neuronal functions but also has been implicated in the improvement of impaired learning and memory [30]. Treatments based on inorganic sulphide salts (including NaHS, Na_2S , and CaS) have been probed as potential treatments to address neurological impairments [32-34]. However, these salts provide immediate H_2S release which may be unsuitable in the treatment of chronic disease states. Furthermore, inorganic sulphide salt administration result in a non-specific delivery of H_2S . Exogenous H_2S is able to impart neuroprotective effects acting as an anti-oxidant, -inflammatory and -apoptotic agent [33]. Since these H_2S donors deliver H_2S not specifically to cellular compartments, a novel mitochondrial targeting slow release H_2S donor, AP39, consisting of the mitochondria targeting TPP^+ group ester-linked with the H_2S donor ADTOH was recently developed [18,17]. The TPP^+ moiety is driven by the plasma membrane potential resulting in a fast uptake across the plasma membrane [35], resulting in a 500-fold accumulation of linked drugs in mitochondria [36]. In addition, the ADTOH moiety is a popular H_2S donor observed to exert its pharmacological effects through a concomitant increase of both GSH and H_2S [37-40] (**Figure 1**).

To compare the effects of AP39 on human neuroblastoma cells, we first differentiated SHSY5Y using RA protocols. This approach has previously been shown to induce important changes to the cell's phenotype and expression of antioxidant machinery while modulating the response of d-SHSY5Y to conditions generating OS [26]. Initially, our approach aimed to verify the appropriate concentration of AP39 that would be non-toxic to cells while improve the mitochondrial bioenergetics. We observed that the condition of differentiation did not alter the cell viability of human neuroblastoma cells to increasing concentrations of AP39 as assessed by MTT assay. Reports by Gero et al 2016, showed that sub-micromolar concentrations of AP39 are safe to use on endothelial cells [18], while our report suggest that human neuroblastoma cells are slightly more resistant to AP39 toxicity as we evidenced tolerability in a micromolar range. Interestingly, H_2S generation from AP39 occurs through multiple steps each of which are affected by various metabolites in the mitochondria [18]. Further, it has been suggested that the H_2S concentration within mitochondria remains below the toxic limit since normalisation of the mitochondrial potential will reduce drug accumulation [36], suggesting that an even at 10 μM , AP39 may not necessarily cause toxicity due to insufficient drug accumulation in mitochondria.

The role of mitochondrial dysfunction in the onset of neurological disorders has been linked to the increased oxygen demand, susceptibility to peroxidation of lipids and imbalance in antioxidant mechanisms [41]. In this regard, the genesis of PD has been implicated at the genetic and

environmental levels [42,43]. As described, AP39 has shown potential for protecting the mitochondrial function and mt-ROS generation by the targeted delivery of H₂S. Our observations evidenced that for both, SHSY5Y and d-SHSY5Y, sub-micromolar levels of AP39 caused accumulation of H₂S in the mitochondria. However, we observed that d-SHSY5Y required a greater concentration of AP39 to significantly improve mitochondrial bioenergetics. Previously, it has been demonstrated that the differentiation of SHSY5Y leads to reduced mitochondrial membrane potential observed as an approximately 200% reduction in mitochondrial TMRM fluorescent probe intensity [44]. Consistent with these observations, we infer that higher concentrations of AP39, perhaps required to normalise the mitochondrial membrane potential, are necessary to exert its effects on the mitochondrial function. Following this rationale, to exert a similar effect in SHSY5Y, less AP39 might be required, resulting in a different response to AP39 in regards to the SHSY5Y differentiation status. However, more analysis and quantification of mitochondrial to cytoplasmic levels of H₂S might be necessary to support this hypothesis.

ROS are emerging as key signalling molecules participating in a myriad of physiological functions [45]. Increased generation and accumulation of ROS, in particular at the mitochondrial level, may result in mitochondrial OS leading to a range of cellular concerns including inflammation and death [9]. The modulation of oxidative damage to the mitochondria may be a novel strategy to address OS-related neuronal disorders with AP39 demonstrating potential to reduce intracellular oxidant production, both *in vitro* and *in vivo*. Interestingly and in contrast to other research groups exploring the potential for AP39 to protect the neuronal functions we observed that human derived cells may have a different behaviour in response to AP39. As we stated before, a range of concentrations of AP39 up to 1 µM may produce beneficial effects against OS. However, other authors exploring mice-derived neurons have shown that up to 0.1 µM AP39 is sufficient to stimulate the cellular bioenergetics while concentrations of 0.250 µM resulted in a inhibition of the cellular bioenergetics [27]. These striking differences in terms of AP39 concentration suggest that human cells types may respond differently to other organisms' cells and stress the importance of exploring the effects of novel molecules using efficient human models. Moreover, similar to previous reports [26], our results regarding d-SHSY5Y, displayed a somewhat OS-resistant phenotype (**Figures 6 and 7**). These effects may be attributed to the variation in the expression of mitochondrial protein levels [26]. Consequently, these observations suggest that a mature neuronal-like cells may better resemble and test the response to H₂S-inhibitory effects. However, the exact molecular mechanisms implicated in these observations remain to be investigated in further experiments.

Conclusions

As far as we are aware, our results provide novel evidence of the potential of AP39 in human neuronal-like cells for the modulation of mitochondrial related-OS and describe the contrasting effects of AP39 on non-differentiated and differentiated human neuroblastoma cells SHSY5Y. These observations suggest that nanomolar to micromolar concentrations of AP39 may be sufficient to exert beneficial effects on the neuronal bioenergetics, including the modulation of the mitochondrial bioenergetics and ROS generation. As neurological disorders are associated with increased OS and defective mitochondria, our results suggest that H₂S-related compounds, in particular AP39, may offer new therapeutic opportunities that warrant further exploration.

Funding:

This work was funded by the Sir Halley Stewart Trust (Ref number 2728). The views expressed within this report are those of the authors and not necessarily those of the Trust.

Conflicts of interests:

Authors declare no conflict of interest.

Authors contributions:

LSA conceived the study, secured funding, performed experiments, drafted and edited the manuscript, MM edited the manuscript and SN performed experiments and edited the manuscript.

Journal Pre-proof

Figures legends:

Figure 1




Figure 1. Chemical Structures depicting ADTOH (5-(4-hydroxyphenyl)-3H-1,2-dithiole-3-thione), TPP⁺ (triphenylphosphonium) and AP39 (TPP⁺ linked to ADTOH).

Figure 2




Figure 2. Differentiation of neuronal SHSY5Y cell line using retinoic acid (RA) in low FBS environment. (A) Bright field images depicting SHSY5Y differentiation with 10 μ M RA and 1% FBS. Neurite extension was effective after 6 days (arrows). (B) Immunocytochemistry against MAP-2

(green) and DAPI (blue). Quantification was performed with 50 cells for each differentiation treatment at day 6. Data= mean \pm SEM. **** p <0.0001 vs non-differentiated SHSY5Y.

Figure 3




Figure 3. Effect of AP39 on SHSY5Y and d-SHSY5Y cell viability. (A) SHSY5Y and (B) d-SHSY5Y we exposed to 0.1-10 μ M AP39 for 24 h and cell viability ascertain by MTT assay. Data= mean \pm SEM. ** p <0.01 vs control (no AP39).

Figure 4




Figure 4. AP39 generates intracellular H₂S. (A) SHSY5Y and (B) d-SHSY5Y were exposed to various concentrations of AP39 for 1 h and intracellular H₂S was detected using Sf7-AM fluorescent probe and mitochondrial localization was monitored by MitoTracker Red as described in Materials and Methods.

Figure 5




Figure 5. Effect of AP39 on resting non-differentiated and differentiated SHSY5Y mitochondrial bioenergetics exposed to increasing concentrations of AP39. (A-C) oxygen consumption expressed by time, their calculated mitochondrial bioenergetics parameters and ATP levels in SHSY5Y and (D-F) d-SHSY5Y. H/V: H₂O₂ (300 μ M) and/or vehicle. O: Oligomycin. F: FCCP. R/A: mixture of antimycin A and rotenone. Data= mean \pm SEM. *p<0.05, **p<0.01 vs control (no AP39). \$ p<0.05 vs AP39.

Figure 6




Figure 6. AP39 improve the mitochondrial respiration in H₂O₂-exposed neuroblastoma cells. Oxygen consumption traces expressed by time and their calculated mitochondrial bioenergetics parameters in non-differentiated (A-B) and differentiated (C-D) SHSY5Y cells. H/V: H₂O₂ (300 μM) and/or vehicle. O: Oligomycin. F: FCCP. R/A: mixture of antimycin A and rotenone. Data= mean ± SEM. *p<0.05, **p<0.01, ***p<0.001 vs control (no AP39). \$ p<0.05 vs AP39.

Figure 7




Figure 7. AP39 ameliorates H₂O₂-induced mt-ROS generation. The generation of mitochondrial specific ROS was detected by fluorescence microscopy using the fluorescent probe MitoSOX Red using 60X magnification. Protein carbonyl content was detected in isolated mitochondria by western blot in (A) SHSY5Y and (B) d-SHSY5Y. VDAC1 (porin) was used as mitochondrial protein loading control. A: Control. B: H₂O₂. C: AP39. D: H₂O₂ + AP39.

Declaration of Competing Interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

References

1. Jellinger KA (2010) Basic mechanisms of neurodegeneration: a critical update. *J Cell Mol Med* 14 (3):457-487. doi:10.1111/j.1582-4934.2010.01010.x
2. 2020 Alzheimer's disease facts and figures (2020). *Alzheimers Dement*. doi:10.1002/alz.12068
3. Blesa J, Trigo-Damas I, Quiroga-Varela A, Jackson-Lewis VR (2015) Oxidative stress and Parkinson's disease. *Front Neuroanat* 9:91. doi:10.3389/fnana.2015.00091
4. Wang X, Wang W, Li L, Perry G, Lee HG, Zhu X (2014) Oxidative stress and mitochondrial dysfunction in Alzheimer's disease. *Biochim Biophys Acta* 1842 (8):1240-1247. doi:10.1016/j.bbadis.2013.10.015
5. Perez Ortiz JM, Swerdlow RH (2019) Mitochondrial dysfunction in Alzheimer's disease: Role in pathogenesis and novel therapeutic opportunities. *Br J Pharmacol* 176 (18):3489-3507. doi:10.1111/bph.14585
6. Exner N, Lutz AK, Haass C, Winklhofer KF (2012) Mitochondrial dysfunction in Parkinson's disease: molecular mechanisms and pathophysiological consequences. *EMBO J* 31 (14):3038-3062. doi:10.1038/emboj.2012.170
7. Chandel NS (2018) Mitochondria: back to the future. *Nat Rev Mol Cell Biol* 19 (2):76. doi:10.1038/nrm.2017.133
8. Hall CN, Klein-Flugge MC, Howarth C, Attwell D (2012) Oxidative phosphorylation, not glycolysis, powers presynaptic and postsynaptic mechanisms underlying brain information processing. *J Neurosci* 32 (26):8940-8951. doi:10.1523/JNEUROSCI.0026-12.2012
9. Pizzino G, Irrera N, Cucinotta M, Pallio G, Mannino F, Arcoraci V, Squadrito F, Altavilla D, Bitto A (2017) Oxidative Stress: Harms and Benefits for Human Health. *Oxid Med Cell Longev* 2017:8416763. doi:10.1155/2017/8416763
10. Zhang X, Bian JS (2014) Hydrogen sulfide: a neuromodulator and neuroprotectant in the central nervous system. *ACS Chem Neurosci* 5 (10):876-883. doi:10.1021/cn500185g
11. Fu M, Zhang W, Wu L, Yang G, Li H, Wang R (2012) Hydrogen sulfide (H₂S) metabolism in mitochondria and its regulatory role in energy production. *Proc Natl Acad Sci U S A* 109 (8):2943-2948. doi:10.1073/pnas.1115634109
12. Whiteman M, Cheung NS, Zhu YZ, Chu SH, Siau JL, Wong BS, Armstrong JS, Moore PK (2005) Hydrogen sulphide: a novel inhibitor of hypochlorous acid-mediated oxidative damage in the brain? *Biochem Biophys Res Commun* 326 (4):794-798. doi:10.1016/j.bbrc.2004.11.110
13. Schreier SM, Muellner MK, Steinkellner H, Hermann M, Esterbauer H, Exner M, Gmeiner BM, Kapiotis S, Laggner H (2010) Hydrogen sulfide scavenges the cytotoxic lipid oxidation product 4-HNE. *Neurotox Res* 17 (3):249-256. doi:10.1007/s12640-009-9099-9
14. Hu LF, Lu M, Tiong CX, Dawe GS, Hu G, Bian JS (2010) Neuroprotective effects of hydrogen sulfide on Parkinson's disease rat models. *Aging Cell* 9 (2):135-146. doi:10.1111/j.1474-9726.2009.00543.x
15. Hu LF, Lu M, Wu ZY, Wong PT, Bian JS (2009) Hydrogen sulfide inhibits rotenone-induced apoptosis via preservation of mitochondrial function. *Mol Pharmacol* 75 (1):27-34. doi:10.1124/mol.108.047985
16. Tiong CX, Lu M, Bian JS (2010) Protective effect of hydrogen sulphide against 6-OHDA-induced cell injury in SH-SY5Y cells involves PKC/PI3K/Akt pathway. *Br J Pharmacol* 161 (2):467-480. doi:10.1111/j.1476-5381.2010.00887.x
17. Szczesny B, Modis K, Yanagi K, Coletta C, Le Trionnaire S, Perry A, Wood ME, Whiteman M, Szabo C (2014) AP39, a novel mitochondria-targeted hydrogen sulfide donor, stimulates cellular bioenergetics, exerts cytoprotective effects and protects against the loss of mitochondrial DNA integrity in oxidatively stressed endothelial cells in vitro. *Nitric Oxide* 41:120-130. doi:10.1016/j.niox.2014.04.008
18. Gero D, Torregrossa R, Perry A, Waters A, Le-Trionnaire S, Whatmore JL, Wood M, Whiteman M (2016) The novel mitochondria-targeted hydrogen sulfide (H₂S) donors AP123 and AP39 protect against hyperglycemic injury in microvascular endothelial cells in vitro. *Pharmacol Res* 113 (Pt A):186-198. doi:10.1016/j.phrs.2016.08.019

19. Ikeda K, Marutani E, Hirai S, Wood ME, Whiteman M, Ichinose F (2015) Mitochondria-targeted hydrogen sulfide donor AP39 improves neurological outcomes after cardiac arrest in mice. *Nitric Oxide* 49:90-96. doi:10.1016/j.niox.2015.05.001
20. Pomierny B, Krzyżanowska W, Jurczyk J, Skórkowska A, Strach B, Szafarz M, Przejczowska-Pomierny K, Torregrossa R, Whiteman M, Marcinkowska M, Pera J, Budziszewska B (2021) The Slow-Releasing and Mitochondria-Targeted Hydrogen Sulfide (H₂S) Delivery Molecule AP39 Induces Brain Tolerance to Ischemia. *22* (15):7816
21. Sanchez-Aranguren LC, Ahmad S, Dias IHK, Alzahrani FA, Rezai H, Wang K, Ahmed A (2020) Bioenergetic effects of hydrogen sulfide suppress soluble Flt-1 and soluble endoglin in cystathionine gamma-lyase compromised endothelial cells. *Sci Rep* 10 (1):15810. doi:10.1038/s41598-020-72371-2
22. Sanchez-Aranguren LC, Espinosa-Gonzalez CT, Gonzalez-Ortiz LM, Sanabria-Barrera SM, Riano-Medina CE, Nunez AF, Ahmed A, Vasquez-Vivar J, Lopez M (2018) Soluble Fms-Like Tyrosine Kinase-1 Alters Cellular Metabolism and Mitochondrial Bioenergetics in Preeclampsia. *Front Physiol* 9:83. doi:10.3389/fphys.2018.00083
23. Ademowo OS, Dias IHK, Diaz-Sanchez L, Sanchez-Aranguren L, Stahl W, Griffiths HR (2020) Partial Mitigation of Oxidized Phospholipid-Mediated Mitochondrial Dysfunction in Neuronal Cells by Oxocarotenoids. *J Alzheimers Dis* 74 (1):113-126. doi:10.3233/JAD-190923
24. Dranka BP, Benavides GA, Diers AR, Giordano S, Zelickson BR, Reily C, Zou L, Chatham JC, Hill BG, Zhang J, Landar A, Darley-Usmar VM (2011) Assessing bioenergetic function in response to oxidative stress by metabolic profiling. *Free Radic Biol Med* 51 (9):1621-1635. doi:10.1016/j.freeradbiomed.2011.08.005
25. Kovalevich J, Santerre M, Langford D (2021) Considerations for the Use of SH-SY5Y Neuroblastoma Cells in Neurobiology. *Methods Mol Biol* 2311:9-23. doi:10.1007/978-1-0716-1437-2_2
26. Schneider L, Giordano S, Zelickson BR, M SJ, G AB, Ouyang X, Fineberg N, Darley-Usmar VM, Zhang J (2011) Differentiation of SH-SY5Y cells to a neuronal phenotype changes cellular bioenergetics and the response to oxidative stress. *Free Radic Biol Med* 51 (11):2007-2017. doi:10.1016/j.freeradbiomed.2011.08.030
27. Zhao FL, Fang F, Qiao PF, Yan N, Gao D, Yan Y (2016) AP39, a Mitochondria-Targeted Hydrogen Sulfide Donor, Supports Cellular Bioenergetics and Protects against Alzheimer's Disease by Preserving Mitochondrial Function in APP/PS1 Mice and Neurons. *Oxid Med Cell Longev* 2016:8360738. doi:10.1155/2016/8360738
28. Ahmad A, Olah G, Szczesny B, Wood ME, Whiteman M, Szabo C (2016) AP39, A Mitochondrially Targeted Hydrogen Sulfide Donor, Exerts Protective Effects in Renal Epithelial Cells Subjected to Oxidative Stress in Vitro and in Acute Renal Injury in Vivo. *Shock* 45 (1):88-97. doi:10.1097/SHK.0000000000000478
29. Rodriguez-Rodriguez A, Egea-Guerrero JJ, Murillo-Cabezas F, Carrillo-Vico A (2014) Oxidative stress in traumatic brain injury. *Curr Med Chem* 21 (10):1201-1211. doi:10.2174/0929867321666131217153310
30. Nagpure BV, Bian JS (2015) Brain, Learning, and Memory: Role of H₂S in Neurodegenerative Diseases. *Handb Exp Pharmacol* 230:193-215. doi:10.1007/978-3-319-18144-8_10
31. Niedzielska E, Smaga I, Gawlik M, Moniczewski A, Stankowicz P, Pera J, Filip M (2016) Oxidative Stress in Neurodegenerative Diseases. *Mol Neurobiol* 53 (6):4094-4125. doi:10.1007/s12035-015-9337-5
32. Panthi S, Manandhar S, Gautam K (2018) Hydrogen sulfide, nitric oxide, and neurodegenerative disorders. *Transl Neurodegener* 7:3. doi:10.1186/s40035-018-0108-x
33. Zhang JY, Ding YP, Wang Z, Kong Y, Gao R, Chen G (2017) Hydrogen sulfide therapy in brain diseases: from bench to bedside. *Med Gas Res* 7 (2):113-119. doi:10.4103/2045-9912.208517
34. Kumar M, Sandhir R (2018) Hydrogen Sulfide in Physiological and Pathological Mechanisms in Brain. *CNS Neurol Disord Drug Targets* 17 (9):654-670. doi:10.2174/1871527317666180605072018

35. Zielonka J, Joseph J, Sikora A, Hardy M, Ouari O, Vasquez-Vivar J, Cheng G, Lopez M, Kalyanaraman B (2017) Mitochondria-Targeted Triphenylphosphonium-Based Compounds: Syntheses, Mechanisms of Action, and Therapeutic and Diagnostic Applications. *Chem Rev* 117 (15):10043-10120. doi:10.1021/acs.chemrev.7b00042
36. Murphy MP (2008) Targeting lipophilic cations to mitochondria. *Biochim Biophys Acta* 1777 (7-8):1028-1031. doi:10.1016/j.bbabi.2008.03.029
37. Giustarini D, Tazzari V, Bassanini I, Rossi R, Sparatore A (2018) The new H₂S-releasing compound ACS94 exerts protective effects through the modulation of thiol homeostasis. *Journal of Enzyme Inhibition and Medicinal Chemistry* 33 (1):1392-1404. doi:10.1080/14756366.2018.1509211
38. Abdul Majid AS, Abdul Majid AMS, Yin Z, Ji D (2013) Slow Regulated Release of H₂S Inhibits Oxidative Stress Induced Cell Death by Influencing Certain Key Signaling Molecules. *Neurochemical research* 38. doi:10.1007/s11064-013-1034-z
39. Sparatore A, Santus G, Giustarini D, Rossi R, Soldato P (2011) Therapeutic potential of new hydrogen sulfide-releasing hybrids. *Expert review of clinical pharmacology* 4:109-121. doi:10.1586/ecp.10.122
40. Heller A, Brockhoff G, Goepferich A (2012) Targeting drugs to mitochondria. *European Journal of Pharmaceutics and Biopharmaceutics* 82 (1):1-18. doi:<https://doi.org/10.1016/j.ejpb.2012.05.014>
41. Sivandzade F, Prasad S, Bhalerao A, Cucullo L (2019) NRF2 and NF- κ B interplay in cerebrovascular and neurodegenerative disorders: Molecular mechanisms and possible therapeutic approaches. *Redox Biol* 21:101059. doi:10.1016/j.redox.2018.11.017
42. Malpartida AB, Williamson M, Narendra DP, Wade-Martins R, Ryan BJ (2021) Mitochondrial Dysfunction and Mitophagy in Parkinson's Disease: From Mechanism to Therapy. *Trends Biochem Sci* 46 (4):329-343. doi:10.1016/j.tibs.2020.11.007
43. Dias V, Junn E, Mouradian MM (2013) The role of oxidative stress in Parkinson's disease. *J Parkinsons Dis* 3 (4):461-491. doi:10.3233/JPD-130230
44. Forster JI, Koglsberger S, Trefois C, Boyd O, Baumuratov AS, Buck L, Balling R, Antony PM (2016) Characterization of Differentiated SH-SY5Y as Neuronal Screening Model Reveals Increased Oxidative Vulnerability. *J Biomol Screen* 21 (5):496-509. doi:10.1177/1087057115625190
45. Schieber M, Chandel NS (2014) ROS function in redox signaling and oxidative stress. *Current biology : CB* 24 (10):R453-462. doi:10.1016/j.cub.2014.03.034